ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.Cancer biology & medicine · 2023Article
- DC-targeting lentivectors for cancer immunotherapy.Immunotherapy advances · 2023Review
- Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses byFrontiers in immunology · 2023Article
- Article
- Cancer Cell-targeted and Activatable Photoimmunotherapy Spares T Cells in a 3D Coculture Model.Photochemistry and photobiology · 2020Article
- Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.NPJ vaccines · 2020Article
- Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells.Oncoimmunology · 2016Article
- CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Oncoimmunology · 2016Article
- Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors.PloS one · 2016Article
- Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.Frontiers in immunology · 2016Review
- CpG Oligonucleotides as Cancer Vaccine Adjuvants.Vaccines · 2015Review
- Review
- Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.New journal of science · 2014Article
- The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Journal of immunology research · 2014Review
- NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.Human vaccines & immunotherapeutics · 2013Article
- Oncolytic viruses as therapeutic cancer vaccines.Molecular cancer · 2013Review
- Trial Watch: Toll-like receptor agonists for cancer therapy.Oncoimmunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Cancer vaccines, to date, have shown limited effect to control the growth of established tumors due largely to effector failure of the antitumor immune responses. Tumor lesion is characterized as chronic indolent inflammation in which the effector function of tumor-infiltrating lymphocytes (TILs) is severely impaired. In this study, we investigated whether the effector function of CD8 TILs could be rescued by converting the chronic inflammation milieu to acute inflammation within tumors. We found that injection of TLR3/9 ligands (polyI:C/CpG) into a tumor during the effector phase of lentivector (lv) immunization effectively rescued the function of lv-activated CD8 TILs and decreased the percentage of T regulatory within the tumor, resulting in a marked improvement in the antitumor efficacy of lv immunization. Mechanistically, rescue of the effector function of CD8 TILs by TLR3/9 ligands is most likely dependent on production, within a tumor, of type-1 IFN that can mature and activate tumor-infiltrating dendritic cells. The effector function of CD8 TILs could not be rescued in mice lacking intact type I IFN signaling. These findings have important implications for tumor immunotherapy, suggesting that type I IFN-mediated activation of tumor-infiltrating dendritic cells within a tumor will most likely restore/enhance the effector function of CD8 TILs and thus improve the antitumor efficacy of current cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.